Skip to main
RLAY

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics is a promising clinical-stage company with a strong focus on precision medicine and a pipeline of advanced product candidates targeting precision oncology and genetic diseases. With promising progress in their various development programs and a planned enrollment update for a Phase 3 study by YE26, there is potential for high demand for the company’s products. Additionally, the recently reported financing and increased confidence in the success of their product candidates could lead to significant growth and a positive market outlook. However, potential concerns such as hyperglycemia and pediatric growth impairment may need to be addressed in future studies to fully realize the potential of their products.

Bears say

Relay Therapeutics is a precision medicine company with a promising pipeline of medicine candidates for oncology and genetic diseases. However, uncertainty remains around the safety and long-term efficacy of its lead drug, zovegalisib. While there is potential for expansion in the treatment of lymphatic malformations, competition and potential limitations in lesion reduction could limit its overall market potential. Furthermore, concerns regarding the tolerability and potential side effects of rival drug alpelisib could benefit Relay Therapeutics in the long run.

RLAY has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Buy based on their latest research and market trends.

According to 11 analysts, RLAY has a Buy consensus rating as of Sep 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.